912
Views
6
CrossRef citations to date
0
Altmetric
Review Articles

The efficacy and safety of JAK inhibitors for atopic dermatitis: a systematic review and meta-analysis

&
Pages 1869-1877 | Received 16 May 2021, Accepted 06 Jun 2021, Published online: 27 Jul 2021
 

Abstract

Background

Atopic dermatitis (AD) is one of the serious global problems. There were wide concerns about whether Janus kinase (JAK) inhibitor was an alternative treatment for AD.

Method

Eight databases were searched from the earliest publication date available to January 2, 2021. We included randomized controlled trials comparing JAK inhibitors with control treatment for AD. Data were pooled using Stata.14 software and performed as mean differences (MD) and risk ratios (RR) with 95% CIs. We did subgroup analysis based on specific outcomes.

Results

A total of studies, ten randomized controlled trials, with 2583 patients were included in the final synthesis. This meta-analysis showed JAK inhibitor resulted in significant improvement on EASI total score (MD = −0.31; 95%CI, −0.46 to –0.17; p = .000; I2 = 90.0%, p = .000) and pruritus numerical rating scale (NRS) score (MD = −1.15; 95%CI, −1.48 to –0.83; p = .000; I2 = 95.9%, p = .000), without the higher risk of total adverse effects (RR = 1.02; 95%CI, 0.90–1.16; p = .745; I2 =27.9%, p = .206).

Conclusions

JAK inhibitor was a promising option for atopic dermatitis. More data and surveillance will be needed to identify efficacy, safety, and the risk of adverse effects.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.